The distinction between routine and complex deprescribing has direct implications for who leads the process, what monitoring is required, and how failure or intolerance should be managed.
Cessation or dose reduction of one medication with a clear risk-benefit indication, no significant interaction risk with remaining agents, and low dependence liability. GP-led with structured follow-up at 4–8 weeks is appropriate.
Examples: SSRI cessation after sustained remission, PPI rationalisation post-acute indication, short-course sedative withdrawal.
Reduction or cessation of one or more agents within a polypharmacy context — particularly where pharmacokinetic or pharmacodynamic interactions, dependence, or high relapse risk are present. Specialist or MDT input is indicated.
Examples: Sequential benzodiazepine and opioid taper in chronic pain with comorbid anxiety; antipsychotic rationalisation in polypharmacy schizophrenia.
| Routine | Complex | |
|---|---|---|
| Scope | Single agent, clear indication for cessation | Multiple agents; interactions, sequencing, and prioritisation required |
| Risk level | Low–moderate Expected withdrawal manageable in primary care |
Higher Rebound syndromes, disease decompensation, severe withdrawal |
| Who leads | GP-led | Specialist or MDT |
| Process | Structured taper with review at 4–8 weeks | Prioritised cessation plan; extended monitoring over months; readiness and sequencing assessment |
| Clinical example | SSRI taper after ≥12 months of sustained remission in first depressive episode | Sequential benzodiazepine + opioid + antidepressant taper in chronic pain with anxiety and prior opioid misuse |
Determinants of complexity include: number of interacting agents under concurrent review; presence of physical or psychological dependence on any agent; risk of relapse or disease decompensation on dose reduction; prior failed deprescribing attempts; significant psychiatric comorbidity; frailty or limited capacity for self-monitoring; and concurrent substance use disorder (which requires a distinct treatment pathway — see below).
Polypharmacy after decades of accumulating prescriptions is common. Risk of falls, cognitive impairment, and drug interactions increases substantially with each added agent. Validated tools — STOPP/START (v3, 2023), Beers Criteria (AGS 2023), and STOPPFrail — are specifically designed for this population. Annual medication review is recommended.
One of the most common and clinically complex deprescribing populations. Typical combinations include opioid analgesics, gabapentinoids (frequently prescribed off-label), antidepressants (duloxetine, amitriptyline for neuropathic pain), and benzodiazepines (for spasm, anxiety, or sleep). Each agent may generate tolerance, dependence, or harm disproportionate to ongoing benefit. Structured, individualised sequential review is recommended — not blanket polypharmacy cessation.
Prescribed beyond their indicated short-term duration for anxiety, insomnia, or panic disorder — at any age. Physical dependence is the expected outcome of prolonged use. The clinical distinction between benzodiazepine dependence and benzodiazepine use disorder must be established before initiating any taper, as the treatment pathway differs substantially.
Hospital admissions, ICU stays, or complex multimorbidity episodes frequently generate a prescribing cascade — sequential addition of medications to manage the side effects or sequelae of preceding prescriptions. Post-acute and post-discharge review should systematically address which agents were initiated for time-limited indications and whether rationalisation is now warranted.
Deprescribing consideration is appropriate in patients with a first or second depressive episode after ≥12–24 months of sustained remission. This is an individual risk-stratified decision — relapse risk varies substantially by episode history, severity, and comorbidity. The evidence-based approach is a very slow, hyperbolic taper with structured monitoring. Recurrent or severe episodes typically warrant indefinite maintenance.
Intellectual disability: antipsychotics are frequently prescribed for behavioural indications without a clear psychiatric diagnosis — guidelines recommend regular review and structured deprescribing attempts. Women planning pregnancy: teratogenic medications should be reviewed and ideally addressed before conception rather than during. Young adults stable on long-term psychotropics may be appropriate candidates for a supervised taper trial after risk-benefit review.
| Medication class | Clinical rationale for review | Caution level |
|---|---|---|
| Benzodiazepines (diazepam, clonazepam, lorazepam, alprazolam) | Physical dependence, cognitive impairment, falls risk, dangerous interaction with opioids and alcohol; intended for short-term use only | Moderate–High |
| Z-drugs (zolpidem, zopiclone, temazepam) | Physical dependence, rebound insomnia on cessation, cognitive effects, falls in elderly; evidence base for long-term efficacy is weak | Moderate |
| Antidepressants (SSRIs, SNRIs, TCAs) | Depression in sustained remission ≥12–24 months; significant discontinuation syndrome risk on rapid cessation, particularly paroxetine, venlafaxine, duloxetine | High — relapse risk |
| Antipsychotics (olanzapine, quetiapine, risperidone, clozapine) | Metabolic syndrome, tardive dyskinesia, QTc prolongation; frequently over-prescribed for insomnia, agitation, or anxiety beyond their indicated conditions | High — psychosis relapse risk |
| Mood stabilisers (lithium, valproate, lamotrigine) | After sustained bipolar remission; post-discontinuation episodes may be more severe and refractory; lithium carries specific rebound mania risk | High — relapse risk |
| Opioid analgesics (oxycodone, morphine, codeine, tramadol) | Chronic non-cancer pain where opioids are not improving functional outcomes; opioid-induced hyperalgesia; tolerance and escalation | Moderate–High |
| Gabapentinoids (pregabalin, gabapentin) | Frequently prescribed off-label for pain, anxiety, and sleep beyond their licensed indications; dependence potential underappreciated; schedule 8 in Victoria from 2023 | Moderate |
| Proton pump inhibitors (omeprazole, pantoprazole) | Prolonged use beyond indication; risks include hypomagnesaemia, C. difficile, and osteoporosis; among the most common candidates for primary care rationalisation | Lower |
Therapeutic alliance. The clinician-patient relationship is the most significant determinant of deprescribing success — more so than the tapering protocol itself. Without a stable therapeutic alliance, patients are unlikely to engage with reduction attempts, tolerate withdrawal discomfort, or return when difficulties arise.
Continuity of care. Consistent, ongoing clinical relationships substantially reduce attrition. Fragmented care — multiple prescribers, frequent handovers, or gaps in follow-up — is among the most common reasons deprescribing attempts fail or are never initiated.
Phenomenological understanding. Patients often attach significant personal meaning to their medications — as a source of safety, identity, or control. Eliciting this, rather than bypassing it, is clinically necessary before initiating any reduction plan.
Recovery-goal alignment. Deprescribing is most likely to be sustained when it is explicitly linked to what the patient identifies as personally meaningful — improved cognition, reduced sedation, better physical function, or reclaimed agency. Reduction framed solely as a clinical objective rarely sustains motivation through difficult phases of a taper.
Flexibility and clinical judgement. In complex polypharmacy, rigid protocol adherence fails. The pace of taper should be adjusted to the individual. A decision to pause, slow, or reverse a taper is clinically appropriate and should be reframed accordingly — not construed as treatment failure. Validated frameworks (Garfinkel algorithm, STOPP/START, Maudsley Guidelines) inform rather than replace clinical judgement.
General practice and non-specialist settings can manage many routine deprescribing scenarios. Referral to an addiction psychiatrist should be considered when:
The distinction between physical dependence — an expected and manageable physiological adaptation to long-term prescribed use — and opioid or benzodiazepine use disorder is a key clinical judgement. DSM-5-TR criteria for substance use disorder (loss of control, continued use despite harm, craving, functional impairment) are the appropriate diagnostic standard. This assessment should inform whether the treatment plan is a structured deprescribing taper or specialist addiction treatment with opioid agonist therapy (OAT) or equivalent.
Pharmacotherapy prescribed as part of addiction treatment — including buprenorphine or methadone for opioid use disorder, and naltrexone, acamprosate, or baclofen for alcohol use disorder — is not a candidate for routine deprescribing. These are evidence-based, mortality-reducing treatments. Any modification must be led by an addiction specialist and framed within addiction medicine principles.
Evidence base and clinical tools: Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry 2019; Horowitz MA, Taylor D. Distinguishing relapse from antidepressant withdrawal. CNS Drugs 2022; Emsley R et al. Antipsychotic discontinuation and relapse in schizophrenia. CNS Drugs 2013; O'Mahony D et al. STOPP/START criteria for potentially inappropriate prescribing in older people, version 3. Age Ageing 2023; By The 2023 American Geriatrics Society Beers Criteria Update Expert Panel. AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. JAGS 2023; Garfinkel D, Mangin D. Feasibility study of a systematic approach to discontinuation of multiple medications in older adults. Arch Intern Med 2010; Taylor DM, Barnes TRE, Young AH. The Maudsley Prescribing Guidelines in Psychiatry, 14th ed. Wiley-Blackwell, 2021; Stahl SM. Stahl's Essential Psychopharmacology, 5th ed. Cambridge University Press, 2021; Australian Deprescribing Network (ADeN) — australiandeprescribingnetwork.com.au.